Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
A fair and balanced NEJM editorial on the Amarin Vascepa REDUCE-IT trial. Co-authored by Dr. John Kastelein and Dr. Erik Stroes, two well respected MD clinical researchers that are very familiar with Resverlogix and Apabetalone.
